In vitro models evaluate lipid-based drug delivery systems for enhancing
solubilization and discharge of the drug. After ingestion, the food particles experience
different physical and chemical changes that prompt their fragmentation into little
pieces and change into less complex atomic groups that can be effortlessly absorbed
into the blood. The dynamic mono and multi-compartmental models have become
more advanced with in vivo information input. The Dynamic Gastric Model (DGM) has
two sections: One is the body and the other is the antrum of the gastric. Up until now,
TNO gastro-Intestinal Model-1(TIM-1) is considered to mimic the closest reproduction
of the energy and flow of human retention. Pancreatic lipase, bile salts, phospholipids
and calcium ions are involved in the intestinal lipolysis. The intestinal lipolysis is
typically assessed by the rate and degree of free unsaturated fats discharged due to the
activity of P-LIP. These can be estimated utilizing diverse strategies such as
colorimetric enzymatic test, gas chromatography and pH-stat titration. The various in
vivo pharmacokinetic aspects of LBFs are formulation and solubilization, dispersibility,
dilution and effect on pharmacokinetics that have been described in this chapter. Other
pharmacokinetic parameters including assimilation and bioavailability improvement,
the impact of excipient choice on bioavailability, lymphatic transport and food effect
reduction have been summarized. This chapter highlights the various in vitro digestion
models and pharmacokinetic aspects of LBFs.
Keywords: Food effect, In vitro digestion models, Intestinal lipolysis, Lymphatic
uptake, pH-stat titration, Pharmacokinetic aspects.
